优势价格
快速发货
品质保证
技术支持
400-920-2911 sales@csnpharm.cn
| 货号 | 产品名 | CAS号 | 信息 |
|---|---|---|---|
| CSN20606 | VH-298 | 2097381-85-4 | VH-298 is a highly affinity inhibitor of E3 ubiquitin ligase VHL inhibitor (Kd = 80-90 nM) which can block the interaction of VHL and HIF-α, thus initiating hypoxic response. |
| CSN20636 | CHIR 98024 | 556813-39-9 | CHIR-98014 is a reversible inhibitor of GSK3α and GSK3β with IC50 of 0.65 nM and 0.58 nM, respectively. |
| CSN20582 | KY1220 | 292168-79-7 | KY1220 inhibits Wnt/β-catenin pathway with IC50 of 2.1 μM in HEK293 cells and it can destabilize both β-catenin and Ras. |
| CSN20594 | Avitinib | 1557267-42-1 | Avitinib selectively inhibits EGFR L858R/T790M mutant with IC50 of 7.68 nM. It used as antineoplastic drug candidate. |
| CSN20602 | N-(3-((2-((3-Fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide maleate | 1557268-88-8 | Avitinib maleate, the maleate salt form of avitinib, selectively inhibits EGFR L858R/T790M mutant with IC50 of 7.68 nM. It used as antineoplastic drug candidate. |
| CSN20604 | SU5205 | 3476-86-6 | Su5205 is an inhibitor of VEGFR2. |
| CSN20607 | AZD5153 6-Hydroxy-2-naphthoic acid | 1869912-40-2 | AZD5153 is an inhibitor of BET/BRD4 bromodomain, the IC50 for BRD4 is 1.7 nM. |
| CSN21182 | SR-4370 | 1816294-67-3 | SR-4370 is an inhibitor of HDAC, with IC50s of 0.13 μM, 0.58 μM, 0.006 μM, 2.3 μM, and 3.4 μM for HDAC1, HDAC2, HDAC3, HDAC8, and HDAC6, respectively. |
| CSN21118 | 7-Hydroxy-4H-chromen-4-one | 59887-89-7 | 7-Hydroxychromone is a Src kinase inhibitor with an IC50 of <300 μM. |
| CSN21143 | GSTO1-IN-1 | 568544-03-6 | GSTO1-IN-1 is a potent glutathione S-transferase omega 1 (GSTO1) inhibitor with an IC50 of 31 nM |
| CSN21203 | 1-(((4-((4-Fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinolin-7-yl)oxy)methyl)cyclopropanamine dihydrochloride | 1360460-82-7 | Anlotinib is an inhibitor of receptor tyrosine kinase (RTK), including vascular endothelial growth factor receptor type 2 (VEGFR2) and type 3 (VEGFR3), and shows antineoplastic and anti-angiogenic activities. |
| CSN21119 | AG 494 | 133550-35-3 | AG-494 is an inhibitor of EGFR with an IC50 value of 0.7 µM and it is inactive toward ErbB2, PDGFR and insulin receptor kinase. |
| CSN21181 | Samuraciclib HCl | 1805789-54-1 | CT7001 HCl is a selective CDK7 inhibitor, with IC50s of 41 nM and 578 nM for CDK7/CycH/MAT1 and CDK2/cycE1, respectively. |
| CSN21126 | Sardomozide 2HCl | 138794-73-7 | Sardomozide 2HCl is an S-adenosylmethionine decarboxylase (SAMDC) inhibitor with an IC50 of 5 nM. |
| CSN21131 | Iadademstat 2HCl | 1431303-72-8 | ORY-1001 trans is a selective irreversible lysine (K)-specific demethylase 1A (KDM1A/LSD1) inhibitor. |
| CSN21179 | GCN2-IN-1 | 1448693-69-3 | GCN2-IN-1 is a potent general control nonderepressible 2 kinase (GCN2) inhibitor with IC50s of <0.3 μM in the enzyme and cell assay. |
| CSN21197 | ABBV-744 | 2138861-99-9 | ABBV-744 is an inhibitor of BDII-selective BET bromodomain that is being investigated to treat AML and metastic castration-resistant prostate cancer. |
| CSN21184 | FL-411 | 2118944-88-8 | FL-411 selectively inhibits BRD4 with an IC50 of 0.43 ± 0.09 μM. |
| CSN21199 | (S)-7-(5-Methylfuran-2-yl)-3-((6-(((tetrahydrofuran-3-yl)oxy)methyl)pyridin-2-yl)methyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-amine | 1202402-40-1 | CPI-444 is an orally administered antagonist of the adenosine A2A receptor. Upon oral administration, CPI-444 binds to adenosine A2A receptors expressed on the surface of immune cells, including T-lymphocytes, natural killer (NK) cells, macrophages and dendritic cells (DCs). |
| CSN21152 | Guadecitabine sodium | 929904-85-8 | Same as guadecitabine, is a dinucleotide antimetabolite of a decitabine linked via phosphodiester bond to a guanosine, with potential antineoplastic activity. |
| CSN21195 | Lazertinib | 1903008-80-9 | Lazertinib is a selective inhibitor of mutant EGFR with lowest activity against EGFR wild type. |
| CSN21166 | 8-Chloro-4-(phenylthio)-1-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]quinoxaline | 303997-35-5 | R-7050 is an antagonist of tumor necrosis factor receptor (TNFR) that towards TNFα. |
| CSN20656 | TRX-818 (sodium salt) | 1256037-62-3 | TRX818 Sodium is an orally bioavailable agent with potential antineoplastic and anti-vasculogenic mimicry (VM) activities. |
| CSN20654 | 3-(1H-1,2,3-Triazol-4-yl)pyridine | 120241-79-4 | 3-TYP is a selective inhibitor of SIRT3. |
| CSN21101 | ARS-1620 | 1698055-85-4 | ARS-1620 is an atropisomeric selective KRASG12C inhibitor with desirable pharmacokinetics. |
| CSN20555 | Derazantinib | 1234356-69-4 | Derazantinib is a fibroblast growth factor receptor (FGFR) inhibitor that has antitumor activity. |
| CSN20624 | TAK-659 HCl | 1952251-28-3 | TAK-659 HCl is a selective inhibitor of spleen tyrosine kinase (Syk) with IC50 of 3.2 nM. |
| CSN20623 | Temuterkib | 1951483-29-6 | LY3214996 can inhibit ERK1 and ERK2 with IC50s of 5 nM. |
| CSN21089 | Thapsigargin | 67526-95-8 | Thapsigargin is a naturally occurring tumor promoter derived from the plant Thapsia garganica. Potent inhibitor of sarco-endoplasmic reticulum Ca2+-ATPases. Causes ER stress; can be used to induce autophagy in mammalian cells. |
| CSN21094 | Tizaterkib | 2097416-76-5 | AZD0364 is an ERK1 and/or ERK2 kinase for the treatment of cancer. |
| CSN21092 | LSZ-102 | 2135600-76-7 | LSZ102 is a potent ERα antagonist and degrader. LSZ102 showed ERα degradation IC50 = 0.2 nM. LSZ102 demonstrated IC50 for MCF-7 cells = 1.7 nM. Upon administration of LSZ102, this agent binds to the ER and induces the degradation of the receptor. This prevents ER activation and ER-mediated signaling, and inhibits the growth and survival of ER-expressing cancer cells. |
| CSN21077 | IRAK4-IN-7 | 1801343-74-7 | CA-4948 is a selective and potent IRAK4 inhibitor which can be used as a therapeutic agent for hematological cancers with dysregulated TLR/MYD88/IRAK4 signaling. CA-4948 exhibits favorable DMPK properties, oral bioavailability, and is well tolerated in mice. Furthermore, CA-4948 is previously shown to exhibit dose-dependent efficacy in ABC-DLBCL MYD88-L265P xenograft tumor models |
| CSN20625 | Darovasertib | 1874276-76-2 | LXS196 is a potent and orally active protein kinase C (PKC) inhibitor used for the treatment of uveal melanoma. |
| CSN20619 | Tyrphostin RG 14620 | 136831-49-7 | Tyrphostin RG14620 is an EGFR inhibitor of tyrphostin family, which selectively reverses ABCG2-mediated multidrug resistance in cancer cell lines. |
| CSN20570 | Guadecitabine | 929901-49-5 | Guadecitabine, aslo known as SGI-110, is a dinucleotide antimetabolite of a decitabine linked via phosphodiester bond to a guanosine, with potential antineoplastic activity. |
| CSN20669 | Leptomycin B | 87081-35-4 | Leptomycin B is an inhibitor of the nuclear export of proteins which acts by binding directly to and inhibiting CRM1/exportin-1. Leptomycin B inhibits the nuclear export of the HIV regulatory protein Rev and stabilizes p53, showing antiviral, antibiotic, antifunal and antitumor in vitro and in vivo. |
| CSN20587 | Lobaplatin | 135558-11-1 | Lobaplatin is a diastereometric mixture of platinum(II) complexes containing a 1,2-bis(aminomethyl)cyclobutane stable ligand and lactic acid as the leaving group. Its antitumour activity results from the formation of DNA-drug adducts, mainly as GG and AG intra-strand cross-links. |
| CSN20655 | CBL0137 | 1197996-80-7 | CBL-0137 is a metabolically stable curaxin that activates p53 with an EC50 value of 0.37 µM and inhibits NF-κB with an EC50 of 0.47 µM. It functionally inactivates the facilitates chromatin transcription complex (FACT), driving the effects on p53 and NF-κB and promoting cancer cell death. |
| CSN20561 | CID5721353 | 301356-95-6 | CID5721353 is a B-Cell Lymphoma 6 inhibitor (BCL6 inhibitor). |
| CSN20595 | PI-273 | 925069-34-7 | PI-273 is a substrate-competitive, specific small molecule inhibitor of PI4KIIα which inhibits the growth of breast cancer cells. |
| CSN20612 | pan-PIM Inhibitor CS11 | 2139294-71-4 | pan-PIM inhibitor CS11 is a pan-PIM kinase inhibitor, which inhibits PIM1 and PIM2 with IC50 of 1 nM and 6 nM, respectively. |
| CSN20642 | SD-1029 | 118372-34-2 | SD1029 is a cell-permeable xanthenedione compound that acts as a JAK2-selective inhibitor. |
| CSN20614 | Ivaltinostat | 936221-33-9 | CG200745 is a hydroxamate-based pan-histone deacetylase inhibitor. |
| CSN20557 | Artepillin C | 72944-19-5 | Artepillin C is a major, biologically active ingredient of Brazilian propolis, possesses anticancer activity against several cancer cells with different tissue origins. |
| CSN20637 | PLS-123 | 1431727-04-6 | PLS-123 is a covalent irreversible Btk inhibitor with potential anti-proliferative activity. |
| CSN20591 | Famitinib | 1044040-56-3 | Famitinib, a structural analogue of sunitinib, is a multi-targeted receptor tyrosine kinase inhibitor which is potential for treatment of renal cell carcinoma, gastrointestinal stromal tumours, pancreatic cancer, and nasopharyngeal carcinoma. |
| CSN20562 | Manumycin A | 52665-74-4 | Manumycin A is an antibiotic that acts as a potent and selective farnesyltransferase (FTase) inhibitor with anti-tumor activity. It inhibits rat brain FTase with a Ki value of 1.2 µM, thereby preventing Ras activation which requires farnesylation at the C-terminus for membrane attachment. |
| CSN20618 | SKI-178 | 1259484-97-3 | SKI-178 is an in vivo active non-lipid sphingosine kinase 1 (SphK1) inhibitor (IC50 = 0.1-1.8 μM), which induces CDK1-dependent apoptosis in human acute myeloid leukemia cell lines. |
| CSN21098 | EBI-2511 | 2098546-05-3 | EBI-2511 is a Highly Potent and Orally Active EZH2 Inhibitor for the Treatment of Non-Hodgkin’s Lymphoma. EBI-2511 showed enzymatic activity and cellular activity of 4.0 and 6.0nM, respectively. EBI-2511 demonstrated excellent in vivo efficacy in Pfeiffer tumor Xenograft models in mouse and is under preclinical development for the treatment of cancers associated with EZH2 mutations. |
| CSN21082 | MK-8353 | 1184173-73-6 | MK-8353, also known as SCH900353, is a potent and orally active ERK1/2 inhibitor and anticancer drug candidate currently being developed by Schering-Plough. MK-8353 exhibited comparable potency with SCH772984 across various preclinical cancer models. |
